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Background: Antimicrobial use is thought to suppress the intestinal microbiota, thereby impairing colonization
resistance and allowing Clostridium difficile to infect the gut. Additional risk factors such as proton-pump inhibitors
may also alter the intestinal microbiota and predispose patients to Clostridium difficile infection (CDI). This
comparative metagenomic study investigates the relationship between epidemiologic exposures, intestinal bacterial
populations and subsequent development of CDI in hospitalized patients. We performed a nested case–control
study including 25 CDI cases and 25 matched controls. Fecal specimens collected prior to disease onset were
evaluated by 16S rRNA gene amplification and pyrosequencing to determine the composition of the intestinal
microbiota during the at-risk period.
Results: The diversity of the intestinal microbiota was significantly reduced prior to an episode of CDI. Sequences
corresponding to the phylum Bacteroidetes and to the families Bacteroidaceae and Clostridiales Incertae Sedis XI
were depleted in CDI patients compared to controls, whereas sequences corresponding to the family
Enterococcaceae were enriched. In multivariable analyses, cephalosporin and fluoroquinolone use, as well as a
decrease in the abundance of Clostridiales Incertae Sedis XI were significantly and independently associated with
CDI development.
Conclusions: This study shows that a reduction in the abundance of a specific bacterial family - Clostridiales
Incertae Sedis XI - is associated with risk of nosocomial CDI and may represent a target for novel strategies to
prevent this life-threatening infection.
Keywords: Intestinal microbiota, Clostridium difficile infection, 16S rRNA gene sequencing, Clostridiales Incertae
Sedis XIBackground
Clostridium difficile infection (CDI) is the leading cause
of nosocomial diarrhea. The incidence and severity of
CDI have been rising over the last decade and outbreaks
continue to occur across the globe [1]. The changing
epidemiology has been linked in part to the emergence
of hypervirulent strains of C. difficile that are resistant to
fluoroquinolones [2]. During the major North American
outbreak of 2003 to 2005, the proportion of complicated* Correspondence: amee.manges@ubc.ca
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reproduction in any medium, provided the orCDI cases requiring colectomy rose to 18% and fatality
rates reached 25% [3,4]. Recognized risk factors for CDI
include advanced age, severe underlying illness, previous
hospitalization, prolonged hospital stay, and most impor-
tantly, exposure to antimicrobials [5]. Broad-spectrum
antimicrobial agents are presumed to disrupt the indigen-
ous intestinal microbiota, thereby impairing colonization
resistance and allowing the establishment and prolife-
ration of C. difficile in the gut. Although nearly all classes
of antimicrobial agents have been associated with CDI,
clindamycin, penicillins, cephalosporins, and more re-
cently fluoroquinolones seem to pose the greatest risk
[5-7].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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alter the intestinal microbiota and predispose patients to
CDI. Gastric-acid suppressive agents like proton-pump
inhibitors (PPIs), may act synergistically with antimicro-
bial agents to disrupt the intestinal microbiota and con-
tribute to CDI development [8]. Epidemiologic evidence
has demonstrated an increased risk of nosocomial CDI
in patients receiving PPI therapy, often concurrently
with antimicrobial agents [9,10]. C. difficile-induced in-
flammation is another factor that may, in conjunction
with antimicrobial use, affect the integrity of the intestinal
microbiota. Research based on mouse colitis models sug-
gests that intestinal inflammation elicited during coloni-
zation by enteric pathogens such as Salmonella and C.
difficile suppresses the indigenous microbiota, allowing
these invaders to grow unimpeded [11].
The objective of this study was to examine the com-
plex relationships between epidemiologic exposures, intes-
tinal bacterial populations, and subsequent development
of CDI in hospitalized patients. In a previous investigation,
we used a microarray with a limited set of 16S rRNA
probes to contrast the composition of the fecal microbiota
between patients who later developed CDI (cases) and
hospitalized controls. In this earlier study, Firmicutes and
Bacteroidetes were found to be significantly and inde-
pendently associated with CDI development [12]. In order
to validate and expand these initial results, we re-assessed
these valuable pre-disease fecal samples by implementing
gold-standard 16S rRNA gene sequencing to obtain a
comprehensive survey of the bacterial taxa that are pre-
sent in the intestinal tract of patients, and by employing
statistical approaches to appropriately deal with patients’
complex exposure histories and the high-dimensional na-
ture of the sequencing data. As the composition of the in-
testinal microbiota is the unifying theme of this study, we
also adjusted our target epidemiologic exposure window
to focus only on medications received prior to stool col-
lection in each patient. We specifically examined (i) pro-
files of intestinal microbiota diversity across patients,
(ii) differences in the pre-disease composition of the intes-
tinal microbiota between CDI cases and control patients,
(iii) the association between intestinal bacterial popu-
lations and risk of CDI after adjusting for exposure to
epidemiologic factors, and (iv) the relationship bet-
ween epidemiologic exposures and intestinal micro-
biota composition. We report that distinctive features
of the intestinal microbiota are associated with CDI
risk in hospitalized patients.
Methods
Study design and subjects
Between September 2006 and May 2007, a total of 599
hospitalized patients were enrolled in a prospective co-
hort study at the Royal Victoria Hospital, Montréal. Adetailed description of the cohort study is available in
Loo et al. [13]. During the study period, 31 patients ex-
perienced one or more defined episodes of CDI. Fecal
specimens collected before the onset of the first CDI
episode (if multiple occurred) were available for 25 of
these patients (cases), and 25 matched controls were se-
lected for inclusion in a nested case–control study. Case
patients were matched to controls based on sex, age (± 5
years) and date of hospitalization (± 2 months). For this
study, a single rectal swab was obtained from each study
subject within 7 days of admission to the hospital. A
questionnaire was administered to all study patients and
collected information concerning demographics, reason
for admission, date of admission and discharge, previous
hospitalization, underlying disease severity (based on
Charlson index), CDI diagnosis, and use of various
medications in the 8 weeks prior to hospital admis-
sion and during hospitalization. Detailed medication
exposures for all patients included in the study are
provided in Additional file 1: Table S1. Information
on nasogastric intubation, aminoglycoside and metro-
nidazole use was collected by the larger study, but
these variables were excluded from further analyses
as exposure was unknown for a large number of pa-
tients. We included exposure to intravenous van-
comycin in our analyses, as evidence suggests that
substantial amounts of the drug can be excreted in
the bowel and may therefore affect the intestinal
microbiota [14]. All participants provided informed
written consent. The human subjects’ protocols for
the cohort and case–control studies were approved
by the Royal Victoria Hospital Internal Review Board
as well as the McGill University Institutional Review
Board (BMB 05–014).
Definitions
CDI was defined by the larger cohort study [13] as fol-
lows: (i) the presence of diarrhea and a positive C. diffi-
cile cytotoxin assay or toxigenic culture, (ii) the presence
of diarrhea without an alternate explanation and an
endoscopic diagnosis of pseudomembranes, or (iii) a
pathological diagnosis of CDI. Diarrhea was defined as
three loose stools within 24 hours for one or more days.
Toxigenic C. difficile culture was performed according
to standard procedures [13].
Fecal specimen processing
Fecal DNA was isolated with use of the DNA IQ System
(Promega Corporation, Madison, WI, USA) and subjec-
ted to whole-genome amplification using the illustra
GenomiPhi V2 DNA Amplification Kit (GE Healthcare
Bio-Sciences Corporation, Piscataway, NJ, USA). Whole-
genome amplification was necessary because of limited
fecal material available from study subjects and to
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The GenomiPhi kit was previously shown to generate
the least amount of bias compared to other DNA ampli-
fication methods [15]. The amplified DNA was purified
with the PureLink PCR Purification Kit (Life Technolo-
gies Inc., Burlington, ON, Canada).16S rRNA gene amplification and sequencing
16S rRNA gene amplification was performed as de-
scribed in the Human Microbiome Project Provisional
16S 454 Protocol [16]. Pyrosequencing was performed at
the McGill University and Génome Québec Innovation
Centre using Roche/454 GS-FLX Titanium technology.Bioinformatic analysis
The open-source software mothur [17] was used to pro-
cess sequences from 16S rRNA gene libraries. Sequences
corresponding to V1-V3 and V3-V5 were binned ac-
cording to primer sequence and analyzed separately.
Reads containing ambiguous bases (Ns), homopolymer
runs greater than 8 bases, inexact match to the MID tag,
or more than two differences from the primer sequence
were excluded from the dataset. Remaining sequences
were aligned against mothur’s Silva reference database
using the NAST algorithm [18]. Potential chimeric se-
quences were detected with mothur’s implementation of
the ChimeraSlayer tool [19] and removed accordingly.
Rare sequence variants that likely arose from pyrose-
quencing errors were merged with their more abundant
parent sequence using a single-linkage pre-clustering al-
gorithm [17].
To determine the proportion of sequences corres-
ponding to C. difficile in patient samples, the entire
set of high-quality reads from V1-V3 and V3-V5 were
BLASTed against a database of 42 annotated 16S rRNA
genes representing 4 finished C. difficile genomes.
BLAST hits with ≥99% identity and ≥99% coverage were
considered to be C. difficile.
In all other analyses, we controlled for differences in
sequencing depth by normalizing the number of high-
quality reads obtained for each sample. For taxonomic
analyses, sequences were annotated using phylum and
family-level assignments with the Bayesian classifier
implemented by the Ribosomal Database Project [20]. A
minimum confidence threshold of 80% was required for
each assignment. For diversity analyses, sequences were
grouped into species-level operational taxonomic units
(OTUs) using the average neighbor clustering algorithm
[21]. OTUs were defined as groups of 16S sequences
sharing at least 97% pairwise identity. The heatmap with
hierarchical clustering was generated with R [22]. Prin-
cipal coordinate analysis (PCoA) was performed with
mothur [17].Statistical analysis
Normalized sequence counts by bacterial phylum and
family were log-transformed, in order to minimize un-
due influence from extreme values. In statistical models
including epidemiologic variables, we considered those
exposures that occurred in the 8 weeks before, as well as
during hospitalization, until the date of stool collection.
In univariate analyses, we first used a penalized least-
squares regression approach (LASSO) to select im-
portant predictor variables [23]. The association between
intestinal bacterial taxa and CDI development was eva-
luated by logistic regression. The association between
epidemiologic exposures and intestinal microbiota com-
position was assessed by Poisson regression. An inter-
action term was included in the latter model to account
for the effect of disease status on intestinal bacterial
populations. Multivariable logistic regression was used
to identify which bacterial taxa remained independently
associated with CDI development after adjusting for the
effects of epidemiologic exposures. Selected variables
included medications that were administered to at
least 8 out of 50 patients, as well as bacterial taxa
that were associated with CDI in the univariate ana-
lysis. Multiscale bootstrapping and analysis of mole-
cular variance (AMOVA) tests were performed with
pvclust and mothur, respectively [17,24]. All other sta-
tistical analyses were performed with Stata (version 11,
StataCorp) or R [22].
Results
Subject characteristics
Twenty-five patients with CDI and 25 age- and sex-
matched controls were retrospectively sampled from
subjects enrolled in a large cohort study at the Royal
Victoria Hospital, Montréal. Characteristics of the study
patients are reported in Table 1. Case and control pa-
tients had similar risk of exposure to C. difficile; the
duration of hospitalization (based on the time from ad-
mission until CDI diagnosis for case patients or until
discharge for control patients) was not significantly dif-
ferent between the groups (P = 0.26, by Mann–Whitney
U-test). Among CDI cases, three patients experienced
more than one defined episode of CDI during the study
period. A single fecal specimen was obtained from each
patient shortly after hospital admission, but before the
onset of the first CDI episode (if multiple occurred) in
the cases (during the at-risk period). Among case pa-
tients, the median interval of time between stool collec-
tion and CDI diagnosis was 5 days.
16S rRNA gene sequencing
Fecal specimens (n = 50; one per subject) were evaluated
by 16S rRNA gene amplification and pyrosequencing to
determine the composition of the intestinal microbiota.





Age, mean years ± SD 70 ± 12.8 69 ± 12.5
Male sex 12 (48) 12 (48)
Charlson comorbidity index, median score (IQR) 1 (1–3) 2 (1–3)
Duration of hospitalizationa, median days (IQR) 7 (4–28) 11 (8–17)
Hospitalization in past 12 months 19 (76) 15 (60)
Reason for hospital admission
Cardiac problem 9 (36) 10 (40)
Gastrointestinal problem 10 (40) 6 (24)
Pulmonary problem 2 (8) 3 (12)
Renal disease 2 (8) 1 (4)
Otherb 2 (8) 5 (20)
Medication usec
H2 blocker 7 (29) 4 (16)
Nonsteroidal anti-inflammatory drug 15 (65) 12 (48)
Proton-pump inhibitor 11 (46) 14 (56)
Steroid 3 (13) 1 (4)
Any antimicrobial agent 21 (91) 13 (52)
Cephalosporind 10 (42) 5 (20)
Fluoroquinolonee 9 (38) 4 (16)
Macrolide 0 (0) 1 (4)
Penicillin 0 (0) 1 (4)
Penicillin with β-lactamase inhibitor 7 (30) 3 (12)
Vancomycinf 5 (22) 3 (12)
Data are number (%) of subjects unless otherwise specified. CDI Clostridium
difficile infection, SD standard deviation, IQR interquartile range. aDuration until
CDI diagnosis for case patients or duration until discharge for control subjects.
bOther reasons include acquired immunodeficiency syndrome, cancer, breast
surgery, anemia, osteomyelitis, neurological or rheumatological problems.
cDefined as use within 8 weeks before or during hospitalization, until stool
collection. Information on steroid, nonsteroidal anti-inflammatory drug, any
antimicrobial agent, penicillin with β-lactamase inhibitor and vancomycin use
was available for 23 out of 25 case patients; information on other medications
was available for 24 out of 25 case patients. None of the patients were
exposed to probiotics, carbapenem, clindamycin, gatifloxacin, levofloxacin,
linezolid, tetracycline or trimethoprim-sulfamethoxazole prior to stool
collection. dIncludes exposure to first-, second-, and third-generation
cephalosporins. eIncludes exposure to ciprofloxacin and moxifloxacin.
fIntravenous administration.
V1-V3 V3-V5
P <0.005 P <0.05
Figure 1 Diversity of the intestinal microbiota across
Clostridium difficile infection (CDI) cases and control subjects.
The 16S rRNA gene sequences were clustered into operational
taxonomic units (OTUs) defined by ≥97% nucleotide sequence
identity. Case patients (n = 25) are colored in red and control
patients (n = 25) are colored in blue. Patients with the lowest
degree of intestinal biodiversity (n = 6; all of these patients are
cases) are shown with open circles. Results are presented for both
V1-V3 and V3-V5 sequence sets. Horizontal lines represent the
median and interquartile range. P values were determined by
Mann–Whitney U-test.
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31,641 per subject) from two segments (V1-V3 and
V3-V5) of the 16S rRNA gene were analyzed. The ta-
xonomic profiles generated from the amplification of
V1-V3 and V3-V5 were in accordance, with a median
Pearson correlation coefficient of 0.90. The majority of
sampled sequences corresponded to Firmicutes (51%
and 55%), Bacteroidetes (34% and 30%) and Proteobac-
teria (8% and 11%) (percentage of V1-V3 and V3-V5 se-
quence sets, respectively).
Based on toxigenic C. difficile culture assays per-
formed by the larger cohort study [13], six patients werefound to be culture-positive on the same date as the
fecal specimen used for sequencing was collected. Of
these, four patients went on to develop CDI (cases), and
two were asymptomatically colonized (controls). In five
of these six culture-positive patients, we detected se-
quences corresponding to C. difficile; sequences could
not be detected in one of the two asymptomatically colo-
nized controls. There were two instances where C. difficile
V1-V3 or V3-V5 sequences comprised >1% of the se-
quence data, and both of these patients showed clinical
manifestation of CDI within the subsequent two days.
Intestinal microbiota diversity
After normalizing for read counts across samples we ob-
served variability in intestinal biodiversity across pa-
tients. Patient samples exhibited a Shannon Index value
range of 0.2 to 3.9 according to V1-V3 data and a range
of 0.3 to 4.2 according to V3-V5 data (Figure 1). Re-
duced biodiversity was significantly related to incipient
CDI. Based on V1-V3 data, all 8 patients (7 patients
based on V3-V5 data) with the lowest degree of mi-
crobial diversity developed CDI, as did 16 (14 based on
V3-V5 data) of the 20 patients with the least diverse
microbiota (Figure 1). Sequence abundances by bacterial
family across patients are presented as a heatmap with
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inter-individual variation in the composition of the fecal
microbiota. Patient samples were divided in two main
profile clusters, A and B, with 93% and 89% support, re-
spectively, by multiscale bootstrapping with 100,000 rep-
licates. Cluster A contained a subset of 8 CDI cases,
while cluster B contained all 25 controls unevenly mixed
with 17 cases.
Differences in intestinal community membership
across patients were assessed by PCoA of Jaccard dis-
tances (Figure 3). In both V1-V3 and V3-V5 sequence
sets, the large majority of intestinal samples from cases
and controls clustered separately in the PCoA plot
(P <0.001 for both V1-V3 and V3-V5 sequence sets, by
AMOVA), although the overall magnitude of variation
explained by principal coordinate 1 was modest (8.1%
for V1-V3 and 10.1% for V3-V5). Samples from case pa-
tients also displayed a greater level of heterogeneity in
their community membership, as shown by the larger
within-group distances in cases compared to controls
(Figure 3; P <0.0001 for both V1-V3 and V3-V5 se-








Figure 2 Intestinal microbiota profiles across Clostridium difficile infec
abundance of V1-V3 sequences by bacterial family (rows) across all patients
equivalent number of reads for each sample. The dendrogram shows hiera
mean) of microbial communities using Canberra distance metric. The bar o
in red and controls (n = 25) are in blue. Patients with the lowest degree of
marked with an asterisk. The staggered bars on the left indicate phylum af
Actinobacteria; Ve, Verrucomicrobia; Fu, Fusobacteria. Other phyla (Lentisph
TM7) and reads that were unclassified at the phylum level, which altogethe
bacterial families are listed on the right of the figure. The color gradient is
reads, as indicated by the scale.Association between intestinal microbiota composition
and Clostridium difficile infection (CDI)
We examined the relationship between intestinal bacterial
taxa and subsequent development of CDI. At the phylum
level, the abundance of Bacteroidetes was significantly
lower in cases compared to controls (Figure 4A). At
the family level, sequences corresponding to Clostri-
diales Incertae Sedis XI (Figure 4B) and Bacteroidaceae
(Figure 4C) were depleted in patients with CDI, while se-
quences assigned to Enterococacceae were enriched
(Figure 4D).
Association between intestinal microbiota composition
and Clostridium difficile infection (CDI) after adjustment
for epidemiologic exposures
We used a multivariable analysis to control for the in-
fluence of antimicrobials and other medications on the
distribution of bacterial taxa that are related to CDI devel-
opment (Table 2). At the phylum level, cephalosporin and
fluoroquinolone use were significantly associated with
CDI development, while a decrease in the proportion of
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A V1-V3 sequence set V3-V5 sequence setB
Figure 3 Intestinal community clustering of Clostridium difficile infection (CDI) cases and control subjects based on principal
coordinate analysis (PCoA). Results are presented for (A) V1-V3 and (B) V3-V5 sequence sets. Case patients (n = 25) are colored in red and
control patients (n = 25) are colored in blue. Patients with the lowest degree of intestinal biodiversity (n = 6; all of these patients are cases) are











Bacteroidetes Clostridiales Incertae Sedis XI
Bacteroidaceae Enterococcaceae
Figure 4 Intestinal bacterial taxa exhibiting significant differences in abundance between Clostridium difficile infection (CDI) cases and
control subjects. The scatter plots show log-transformed 16S sequence counts for the corresponding bacterial (A) phylum or (B-D) family in
cases (n = 25) versus controls (n = 25). Results are presented for both V1-V3 and V3-V5 sequence sets. Patients with the lowest degree of
intestinal biodiversity (n = 6; all of these patients are cases) are shown with open circles. Horizontal lines represent the median and interquartile
range. P values were determined by logistic regression.
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Table 2 Multivariable analysis of epidemiologic exposures and intestinal bacterial taxa related to Clostridium difficile
infection (CDI) development
Variable Phylum-level analysis
V1-V3 sequence set V3-V5 sequence set
P valuea Coefficient signb P valuea Coefficient signb
Bacterial phylum
Bacteroidetes 0.048 - 0.061 -
Shannon diversity 0.187 - 0.455 -
Medication usec
H2 blocker 0.319 - 0.271 -
Nonsteroidal anti-inflammatory drug 0.684 + 0.989 +
Proton-pump inhibitor 0.443 - 0.467 -
Cephalosporin 0.016 + 0.009 +
Fluoroquinolone 0.038 + 0.018 +
Penicillin with β-lactamase inhibitor 0.228 + 0.424 +
Vancomycind 0.278 + 0.116 +
Family-level analysis
V1-V3 sequence set V3-V5 sequence set
P valuea Coefficient signb P valuea Coefficient signb
Bacterial family
Bacteroidaceae 0.073 - 0.051 -
Clostridiales Incertae Sedis XI 0.015 - 0.025 -
Enterococcaceae 0.942 + 0.246 +
Shannon diversity 0.728 + 0.238 +
Medication usec
H2 blocker 0.384 - 0.318 -
Nonsteroidal anti-inflammatory drug 0.921 + 0.605 +
Proton-pump inhibitor 0.674 - 0.558 -
Cephalosporin 0.020 + 0.027 +
Fluoroquinolone 0.045 + 0.061 +
Penicillin with β-lactamase inhibitor 0.692 + 0.850 -
Vancomycind 0.423 + 0.193 +
aP values were determined by multivariate logistic regression. bA positive sign indicates that 16S sequence abundance (for bacterial taxa) or number of patients
exposed (for medications) was higher among patients with CDI than among controls, while a negative sign indicates that 16S sequence abundance or number of
patients exposed was lower among patients with CDI. cDefined as use within 8 weeks before or during hospitalization, until stool collection. dIntravenous
administration.
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quency of Clostridiales Incertae Sedis XI were significant
risk factors for CDI, while fluoroquinolone exposure was
of borderline significance.
Association between epidemiologic exposures and
intestinal microbiota composition
The impact of antimicrobials and other medications on
the composition of the intestinal microbiota in patients
was examined. We detected a significant association
between exposure to penicillin with β-lactamase inhi-
bitor and an increase in the abundance of Firmicutes(Figure 5). No other medications were observed to be
associated with differences in intestinal microbiota
composition.
Assessment of six patients with least diverse intestinal
microbiota
Six case patients exhibited the lowest degree of microbial
diversity (V1-V3 and V3-V5 Shannon Index value <1.7) of
all study subjects (Figure 1). Although medication infor-
mation was missing for one case, there was no indication
that the other five low diversity cases differed from the
rest of patients in terms of exposure to antimicrobials or
P <0.05 P <0.05
V1-V3 V3-V5
Figure 5 Exposure to penicillin with β-lactamase inhibitor is
associated with an increase in Firmicutes. The scatter plot shows
log-transformed 16S sequence counts for Firmicutes in patients that
were exposed (n = 10) or unexposed (n = 38) to penicillin with
β-lactamase inhibitor. Results are presented for both V1-V3 and
V3-V5 sequence sets. Patients with the lowest degree of intestinal
biodiversity (n = 5) are shown with open circles. Horizontal lines
represent the median and interquartile range. P values were
determined by Poisson regression. Note that data on exposure to
penicillin with β-lactamase inhibitor was missing in two patients,
including one of the patients with the lowest degree of intestinal
biodiversity; these are not depicted.
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for all medications, by Fisher’s exact test). In the heatmap,
these six low diversity cases were spread across clusters A
and B and did not share a common taxonomic profile
(Figure 2). However, these patients were clearly positioned
away from the cluster of controls in the PCoA plot
(Figure 3). The enrichment in Enterococacceae was
observed in all of the six patients with reduced bio-
diversity (Figure 4D).
Discussion
Exposure to antimicrobials or antimicrobials in conjunc-
tion with other medications is thought to alter the intes-
tinal microbiota and impair colonization resistance to C.
difficile. By obtaining fecal specimens in the at-risk
period prior to CDI onset, we were able to evaluate the
impact of epidemiologic exposures and intestinal mi-
crobiota composition on CDI risk. Not only do our
results confirm the existence of a compromised gut
microbiota in CDI patients, but we were able to iden-
tify specific epidemiologic and microbiota factors that
are significantly and independently associated with
CDI development.Several studies have observed a reduced microbial di-
versity in patients with CDI or other diseases, including
irritable bowel syndrome and obesity [25-28]. Our re-
sults confirm that low diversity is related to CDI devel-
opment. However, this feature was not found to be an
independent predictor of CDI in the multivariable ana-
lysis. Reduced diversity may be a non-specific marker of
disease.
The levels of Bacteroidetes and Enterococcaceae were
markedly altered in patients that were about to experi-
ence CDI; however, after adjustment for medication use,
these associations were no longer significant. Ferreira
et al. have suggested that Bacteroidetes may confer
resistance to infectious colitis by protecting against
pathogen-mediated intestinal inflammation [29]. Intri-
guingly, the observed increase in Enterococcaceae ap-
peared to be mostly driven by a subset of six cases with
the lowest degree of intestinal diversity. Enterococci are
opportunistic microorganisms that can, like C. difficile,
exploit the reduced biodiversity of the intestinal ecosys-
tem to expand their population. This idea is consistent
with studies showing increased levels of enterococci in
the gut following treatment with extended-spectrum
antimicrobial agents [30,31]. In a study by Lawley and
colleagues, antibiotic treatment of mice asymptomati-
cally colonized with C. difficile resulted in a dramatic re-
duction in intestinal microbial diversity accompanied by
an expansion of Escherichia coli and enterococci which
triggered the overgrowth of C. difficile [32].
In the multivariable analysis, cephalosporin and
fluoroquinolone exposure, as well as a decrease in the
abundance of Clostridiales Incertae Sedis XI were signifi-
cantly associated with CDI development. According to
current taxonomic lineages, C. difficile (which is part of
the Peptostreptococaceae family) and the bacterial family
Clostridiales Incertae Sedis XI belong to the same order
(Clostridiales) [20,33]. Therefore, the depletion of Clos-
tridiales Incertae Sedis XI that preceded CDI onset may
indicate an absence of competitive exclusion or other
colonization resistance mechanisms operating in the in-
testinal microbiota of these patients. Studies involving
animal models suggest that competition for similar nu-
trient sources or ecological niches mediated by closely
related bacterial groups that are already established in
the gut may prevent invasion by pathogenic relatives
such as C. difficile [34]. A randomized clinical trial to
evaluate the safety and efficacy of colonization with non-
toxigenic C. difficile for the prevention of recurrent CDI
is currently underway [35].
We have demonstrated an association between the use
of penicillin with β-lactamase inhibitor and an increase
in the abundance of Firmicutes. Culture-based analyses
of the human fecal microbiota have previously shown that
administration of amoxicillin-clavulanic acid (a penicillin
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aerobic Gram-positive cocci, most of which belong to
Firmicutes [36].
In our previous 16S rRNA microarray-based investiga-
tion of the same set of samples, we could not establish
that low intestinal microbial diversity is associated with
CDI development [12]. In this study, high-resolution se-
quencing along with analyses performed at a lower
phylogenetic level allowed us to capture most of the
bacterial diversity, and we were able to confirm that re-
duced diversity is related to CDI. This study also vali-
dates our previous observation that an enrichment of
Enterococcaceae and a depletion of Bacteroidetes or
Clostridiales Incertae Sedis XI are significantly associ-
ated with CDI development [12]. We did observe higher
levels of Firmicutes among our CDI patients, as reported
previously, but the association was not statistically sig-
nificant in the current sequence-based study (P = 0.09,
by logistic regression).
Other authors have assessed intestinal microbiota al-
terations in patients with an initial or recurrent episode
of CDI [25-27,37]. However, these investigations did not
account for the influence of antimicrobials and other
medications in the analysis of microbial profiles associ-
ated with CDI. Moreover, previous studies have typically
assessed microbiota composition at the time of CDI
diagnosis, when the results are likely confounded by the
effects of the disease itself (that is, diarrhea and intes-
tinal inflammation) and the effects of CDI treatment on
the intestinal ecology. We did observe reduced levels of
the Bacteroides-Porphyromonas-Prevotella group and
increased levels of facultative anaerobes in patients
with CDI, as reported elsewhere, but we did not find
a significant association with members of the ente-
robacteria, bifidobacteria or lactobacilli [25,26,37]. Among
our 25 case patients, 3 experienced multiple CDI epi-
sodes. We did not observe specific microbiota altera-
tions that could distinguish these patients from other
CDI cases and the small number of patients pre-
cluded any further analyses. Whether specific micro-
biota signatures can predict the eventual development
of recurrent CDI (as opposed to a single CDI episode) re-
mains to be addressed.
De La Cochetière et al. investigated the relationship
between dominant gut bacterial species and subsequent
acquisition of C. difficile in outpatients receiving anti-
microbial therapy. Fecal samples obtained prior to the
initiation of antimicrobial treatment were analyzed by
temporal temperature gradient gel electrophoresis and
the resulting microbial profiles could accurately predict
the risk of C. difficile acquisition in these subjects [38].
Similarly, our results support the idea that certain pa-
tients have an existing predisposition to CDI when they
are admitted to the hospital; their intestinal microbiotamay be less resilient to the effects of antibiotics or more
permissive to the invasion of C. difficile.
This study is limited by biases inherent to bacterial
DNA extraction (due to differential lysis efficiency),
whole-genome amplification and 16S rRNA gene ampli-
fication (due to species coverage of the primers and vari-
able numbers of 16S rRNA gene copies per genome),
which may contribute to under- or over-representation
of certain bacterial taxa. Our limited sample size also
made it difficult to account for variability in microbiota
profiles due to differences in underlying disease and
treatment histories across patients. Despite these limita-
tions, important differences in the abundance of key
bacterial taxa were apparent and clearly distinguished
CDI cases from control patients.
Conclusions
Although the association between antimicrobial use and
CDI is well established, specific alterations to the intestinal
microbiota and how they contribute to disease deve-
lopment are poorly described. In this study, we identified
specific epidemiologic and microbiota factors that are as-
sociated with CDI risk in hospitalized patients. Based on
multivariable analyses, independent risk factors for CDI
included cephalosporin and fluoroquinolone exposure, as
well as a depletion of Clostridiales Incertae Sedis XI. This
important novel finding may eventually lead to the elabo-
ration of targeted microbiota interventions to prevent the
development of CDI in high-risk patients.
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